Background and Purpose A randomized, double-blind, placebo-controlled multicenter trial was conducted to test the hypothesis that nimodipine would improve the functional outcome in acute ischemic hemispheric stroke.
Background and Purpose A randomized, double-blind, placebo-controlled multicenter trial was conducted to test the hypothesis that nimodipine would improve the functional outcome in acute ischemic hemispheric stroke.
Methods A total of 350 patients were randomized to nimodipine 120 mg/d PO or matching placebo for 21 days. Randomization was stratified by onset of therapy, age, and stroke severity. Treatment was begun within 48 hours of onset. The patients had neurological evaluation on admission, on days 1, 7, and 21, and at 3 and 12 months. The primary end points were Rankin grade, neurological score, and mobility at 12 months.
Results We did not find any differences in the functional outcome between the treatment groups or between the stratified subgroups. We were also unable in post hoc analyses to T he important role of calcium influx in cell death during cerebral ischemia has been known since the late 1970s. This has been the theoretical basis for the clinical trials with nimodipine, a dihydropyridine calcium antagonist, in the treatment of acute ischemic stroke (Table 1) . The results of the earliest trials seemed to fulfill expectations, 1 -3 but later trials have for the most part provided negative results. 4 -8 In one study the recovery even seemed to be delayed in the nimodipine group compared with placebo. 6 However, patients with moderate to severe neurological deficits, 57 those who had the treatment started within 12 to 18 hours of onset, 8 and those with normal findings on the initial computed tomographic (CT) scan 8 might have benefited from nimodipine treatment.
The aim of the present double-blind, placebo-controlled, stratified multicenter study was to determine the safety and efficacy of nimodipine 120 mg/d PO on the functional outcome of acute ischemic hemispheric stroke.
find any groups of patients who benefited from nimodipine. During the first month and at 3 months the case-fatality rate was higher in the nimodipine-treated patients than in those on placebo (/"=.004 and P=.O3O, respectively), but at the 1-year follow-up this difference had lost statistical significance. During the first week nimodipine had a statistically significant lowering effect on both systolic (P=.005) and diastolic (/ ) =.O13) blood pressure. Conclusions Nimodipine did not improve the functional outcome of acute ischemic hemispheric stroke. The early case-fatality rate was higher in the nimodipine group, possibly due to the blood pressure-lowering effect of nimodipine. 
Subjects and Methods
The present study was started in August 1984, and patient accrual continued until the end of December 1989. Before launching the study, it was approved by the ethics committees of each of the three participating hospitals. Patients were eligible for the trial if they had symptoms and signs of acute ischemic hemispheric stroke, were admitted within 48 hours of stroke onset, and were 16 to 69 years of age and if the CT was compatible with the clinical diagnosis and informed consent was obtained from the patient or a near relative.
Exclusion criteria were unconsciousness; inability to swallow; rapidly improving symptoms and signs (possible transient ischemic attack); dependence in activities of daily living before stroke; brain stem infarction; complicated migraine; pregnancy; overt renal, hepatic, or cardiac failure; severe systemic infection; serious psychiatric disturbance; and terminal malignancy.
On admission, demographic data, previous medical history, and current medication were recorded. The patients had detailed general and neurological assessment, and CT was scheduled to be performed within the first days of admission. In addition, electrocardiography, chest x-ray, and routine hematologic and urine tests were performed.
The neurological examination, which was repeated on days 1, 7, and 21 and at 3 and 12 months after admission, included level of consciousness, orientation, speech, visual fields, limb paresis, facial paresis, gaze paresis, and reflexes. However, in many cases not all of these items can be assessed, eg, even moderate dysphasia may preclude the evaluation of orientation and a reliable assessment of the visual fields. Therefore, we used in the analysis a sum score consisting of the three most relevant items that could be evaluated in all patients from the time of onset: (1) level of consciousness (0, normal; 10, drowsy but rational; 20, confused but obeys commands; 30, no response to commands but localizing pain; 40, reflex response to pain; 50, no response to pain); (2) severity of hemiparesis, upper and lower limb separately (0, normal; 5, minimal weakness; 10, moderate weakness but able to lift the limb against gravity; 15, slight movement only; 20, total paralysis); and (3) gaze paresis (0, not present; 10, present). The maximal sum of these three items is 100 points. In the evaluation we also included mobility (0, walks unaided; 1, walks aided; 2, stands unaided; 3, stands aided; 4, sits unaided; 5, sits aided; 6, bedridden) and bladder control (normal, incontinent). Functional outcome at 3 and 12 months was assessed using the Rankin grades.
9 Grades 1 and 2, representing independence, were considered a good outcome. In case of death the interval from onset of stroke was calculated. The cause of death was based on clinical data and on necropsy findings, if available.
The primary end points were functional outcome (Rankin grade), mobility, and neurological score at 12 months. In addition, survival and domicile at the end of follow-up were analyzed.
The patients were randomized to nimodipine or placebo treatment after stratification into subgroups by the time interval from onset of stroke to administration of the drug (<24 hours versus 24 to 48 hours), age (16 to 59 years versus 60 to 69 years), and the severity of stroke (major versus minor). The stroke was considered major if the level of consciousness was reduced and/or if the patient was unable to lift both paretic limbs against gravity. All other strokes were classified as minor. The nimodipine and placebo tablets, which were of identical appearance, were randomized and provided in numbered vials by Bayer AG. The patients received 120 mg nimodipine (30 mg four times per day) or a matching placebo for 21 days. Each hospital was provided with sealed envelopes with the codes of single patients for emergency situations. None of the envelopes were opened during the trial.
The sample size of the trial was estimated assuming that 60% of the patients would achieve independence (Rankin grades 1 and 2) spontaneously during the 12-month followup 10 ' 11 and that this proportion could be increased up to 75% by nimodipine treatment. Using a power of 80% and a two-sided 5% significance test, a minimum of 330 patients was calculated as necessary to detect an improvement of this magnitude.
The significance of differences of proportions was analyzed by x 2 test » °f ordinal data by the Mann-Whitney U test, and of mean values by the / test. The confidence intervals of means were calculated according to Altman and Gardner 12 and those of medians according to Campbell and Gardner. 13 Differences in survival curves were analyzed by the log-rank test.
Results
A total of 350 patients were randomized, 174 in the placebo and 176 in the nimodipine group. Baseline characteristics, except the prevalence of fresh infarcts on CT, were similar in both treatment groups (Table 2) . CT was performed on the day of onset in 41% and 43% of patients in the nimodipine and placebo groups, respectively; the corresponding figures for the first 3 days were 89% and 90%. The prevalence of a fresh infarct on CTs performed on the day of onset, but not later, was significantly higher in the nimodipine than in the placebo group: 58 of 70 (83%) versus 43 of 71 (61%) (* 2 =8.6, P=.003). However, the mean neurological scores of patients with a fresh infarct on CT were identical (32.4 points) in both treatment groups. In 13 (3.7%) patients CT was either not performed (early death, diagnosis by necropsy) or the films were not traced. Seventy percent of the patients were married, and 30% were either widowed, divorced, or single. Ninety-nine percent were living in private households, three of four with spouse or other relative. The stroke was considered cardioembolic in 35 (10%) of the patients; 29 patients (10 on nimodipine, 19 on placebo) had atrial fibrillation, and another 6 patients had either recent (<3 months) myocardial infarction or prosthetic valves.
Medication was started in both treatment groups 20 hours (average) after stroke onset. Treatment was begun within the first 6 hours in 33 (19%) patients in the nimodipine group and in 23 (13%) in the placebo group. The corresponding figures for the first 12 hours were 63 (36%) and 71 (41%), respectively.
Fifty-one (15%) patients died during the follow-up, 22 in the placebo and 29 in the nimodipine group. The index stroke was significantly more often fatal in the nimodipine group, but the other causes were evenly distributed (Table 3) . Twelve-month survival was slightly but not significantly better in the placebo group (Figure) . However, during the first 30 and 90 days, the patients on nimodipine had higher case-fatality rates than those on placebo (/>=.004 and P=.O3O, respectively). Five (71%) of the 7 deaths during the first 30 days of onset in the placebo group occurred in patients with On admission and at 1 year the neurological scores of patients in both treatment groups were similar ( Table  4 ). The patients who died during the follow-up had on average more severe neurological deficits on admission, especially in the nimodipine group. The median scores were even higher in patients dying of the index stroke. Nimodipine treatment of patients with major stroke seemed to delay the improvement of the neurological score during the first 3 weeks. The first reliable assessment of mobility was made on day 7, when 56% of patients on placebo and 58% on nimodipine were able to walk, with or without assistance, and 9% and 11%, respectively, were bedridden.
The mean systolic and diastolic blood pressures measured on admission were similar in the treatment groups (Table 5) . During the first week a significant decrease in the pressure levels occurred in both treatment groups, which was more marked in the nimodipine group. The differences between nimodipine and placebo were statistically significant for systolic blood pressure on day 7 and for diastolic blood pressure on day 1. Those who eventually died during the study period had slightly but nonsignificantly higher systolic and diastolic blood pressure levels on admission.
The functional outcome of patients in both treatment groups at 3-and 12-month follow-ups was similar as measured by Rankin grades, mobility, and neurological score ( Table 6 ). The same was true for domicile. We found no differences in the functional outcome if the time of the first dose of medication (^12 hours versus >12 hours), age (<60 years versus 60 to 69 years), severity of stroke (minor versus major), or findings on admission CT (recent brain infarct present versus absent) were taken into account. Adverse effects were rare; two patients in the placebo group discontinued the medication (one experienced hypotonia, and the other did not comply with the medication). Four patients in the nimodipine group stopped the treatment prematurely (2 were unable to swallow, 1 suffered from infectious diarrhea, and 1 patient forgot to take the tablets after discharge on day 13).
Discussion
In the present study we were unable to find any benefits of nimodipine treatment on functional outcome at 3 months and 1 year after acute ischemic hemispheric stroke. Our results agree with the double-blind and placebo-controlled trials of nimodipine in acute brain infarction published in the 1990s. 4 " 8 In the earlier studies, post hoc analysis of some subgroups has given promising treatment results, eg, moderately severe or severe strokes might benefit from nimodipine treatment, 57 men may respond better than women, 1 a daily dose of 120 mg may be better than 240 mg, 38 treatment started within 18 hours after onset might be advantageous, 8 and a normal CT scan obtained within 18 hours after onset 8 seems to have positive effects on the results of nimodipine treatment. We used stratified randomization to be able to analyze the effects of nimodipine on functional outcome according to the severity of stroke, time of beginning of treatment, and age of the patient. None of these stratification groups benefited from nimodipine treatment; in fact, the improvement of patients with major stroke was slightly delayed during nimodipine treatment. The same was true in several post hoc analyses, including patients beginning treatment within 12 hours with a moderate to severe stroke, who were reported to fare better on nimodipine than placebo.
14 The 1-and 3-month case-fatality rates were significantly higher in the nimodipine group. The median admission neurological scores of survivors were similar in both treatment groups and were lower compared with the patients who died during the follow-up, especially those on nimodipine. The prevalence of a fresh infarct on CT was significantly higher in the nimodipine group, and most of this difference depended on CT examinations performed during the first 24 hours. The mean admission neurological scores of the patients with a fresh infarct were identical in both treatment groups, but the patients in the nimodipine group who died during the first 30 days of onset had slightly (nonsignificantly) more severe neurological defects on admission than those on placebo treatment.
The difference in the prevalence of a fresh infarct on CT per se may not explain the difference in the early case-fatality rates between the treatment groups. It is possible that patients with both a fresh infarct on CT and more serious neurological signs do not tolerate treatment with nimodipine. Whether this is due to the blood pressure-lowering effect of nimodipine (which, according to our results, is not minimal, as has been reported in a study of a small number of patients 15 ) remains a matter of discussion. A similar explanation for the untoward results has been given in the prematurely terminated Intravenous Nimodipine West European Stroke Trial (INWEST). 16 The cytoprotective effects of nimodipine may be limited because calcium influx is prevented only through the voltage-sensitive calcium channels but obviously not through the agonist-operated channels, a principle not known when we started our study. On the other hand, ischemia-induced failure of calcium pump mechanisms and intracellular calcium release are not affected by calcium blocking agents. 1718 Another possible explanation for the disappointing results might be that the treatment was started too late. Medical treatment of ischemic stroke started within 4 to 6 hours of onset or even earlier has been advocated, 19 and a delay of less than 6 hours has been the prerequisite in trials on thrombolytic therapy. 20 This requires that the patient arrive at the hospital early and that treatment is started without delay. With patient, paramedic, and physician education this may be achieved. 21 
